Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade
Tan, D.S.W.
Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology 35(24): 2735-2736
2017
ISSN/ISBN: 0732-183X
PMID: 28715246
DOI: 10.1200/jco.2017.73.6215
Accession: 059487357
PDF emailed within 0-6 h: $19.90
Related References
Chen, J.; Chen, Y.; Feng, F.; Chen, C.; Zeng, H.; Wen, S.; Xu, X.; He, J.; Li, J. 2018: Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer Journal of Thoracic Disease 10(12): 6711-6721Arbour, K.C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W.Victoria.; Hendriks, L.E.L.; Sabari, J.K.; Caramella, C.; Plodkowski, A.J.; Halpenny, D.; Chaft, J.E.; Planchard, D.; Riely, G.J.; Besse, B.; Hellmann, M.D. 2018: Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(28): 2872-2878
Jove, M.; Vilariño, N.; Nadal, E. 2019: Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer Translational Lung Cancer Research 8(Suppl. 4): S364-S368
Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; Hollmann, T.; Schalper, K.A.; Gainor, J.F.; Shen, R.; Ni, A.; Arbour, K.C.; Merghoub, T.; Wolchok, J.; Snyder, A.; Chaft, J.E.; Kris, M.G.; Rudin, C.M.; Socci, N.D.; Berger, M.F.; Taylor, B.S.; Zehir, A.; Solit, D.B.; Arcila, M.E.; Ladanyi, M.; Riely, G.J.; Schultz, N.; Hellmann, M.D. 2018: Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(7): 633-641
Yamane, H.; Isozaki, H.; Takeyama, M.; Ochi, N.; Kudo, K.; Honda, Y.; Yamagishi, T.; Kubo, T.; Kiura, K.; Takigawa, N. 2015: Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines American Journal of Cancer Research 5(4): 1553-1557
Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
Iafolla, M.A.J.; Juergens, R.A. 2017: Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Frontiers in Oncology 7: 67
Khunger, M.; Rakshit, S.; Pasupuleti, V.; Hernandez, A.V.; Mazzone, P.; Stevenson, J.; Pennell, N.A.; Velcheti, V. 2017: Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials Chest 152(2): 271-281
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P-Guillaume. 2019: Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer European Journal of Cancer 115: 107-110
Sun, L.; Yang, H.; Mao, Y. 2019: Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids Annals of Translational Medicine 7(Suppl. 8): S287
Grecea, M.; Marabelle, Aélien.; Ammari, S.; Massard, C.; Champiat, Séphane. 2020: Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature Oncologist 25(5): 369-374
Fukuda, M.; Yamaguchi, H.; Mukae, H.; Ashizawa, K. 2018: Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer Journal of Thoracic Disease 10(Suppl. 33): S4082-S4084
Zhang, L.; Zhao, Y.; Tu, Q.; Xue, X.; Zhu, X.; Zhao, K-Nan. 2020: The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy Current Medicinal Chemistry 2020
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61